MedTrace Logo

PSMA-PET Directed Radiation Therapy for High-Risk Prostate Cancer

NCT07291557 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2025-12-18

No results posted yet for this study

Summary

In this study, prostate cancer patients whose cancer has not spread to the lymph nodes will receive radiation therapy targeted to the prostate and nearby tissues with or without whole pelvis radiation therapy. PSMA imaging will be used to visualize prostate cancer prior to starting the trial.

Conditions

Interventions

RADIATION

Prostate Only Radiation Therapy (PORT)

6800cGy in 25 daily fractions to the prostate and surrounding tissues

RADIATION

Prostate + Whole Pelvis Radiation Therapy (P-WPRT)

6800cGy to the prostate and surrounding tissues + 5000cGy to the whole pelvis in 25 daily fractions.

Sponsors & Collaborators

  • Cross Cancer Institute

    collaborator OTHER

  • AHS Cancer Control Alberta

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2031-05-31
Completion
2036-05-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07291557 on ClinicalTrials.gov